MabCure Begins Clinical Trial for Antibody Technology for Use as Cancer Diagnostic | GenomeWeb

This story originally ran on Jan. 14.

By Tony Fong

Startup antibody biotech firm MabCure has begun a clinical trial for a monoclonal antibody-based diagnostic it has developed for ovarian cancer.

The trial, which will be done in collaboration with Ramathibodi Hospital at Mahidol University in Bangkok, Thailand, will evaluate the efficacy of the antibodies in detecting the cancer, and represents the first step in MabCure's proposed path to get a diagnostic test approved in Europe.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.